Incidence of depression in kidney transplant recipients in South Korea: a long-term population-based study

Semin Cho1, Sehoon Park2, Ji Eun Kim3, Mi-yeon Yu4, Seon Ha Baek5, Kyungdo Han6, Hajeong Lee7, Dong Ki Kim7,8, Kwon Wook Joo7, Yon Su Kim7 & Yong Chul Kim7

Depression is associated with impaired quality of life and increased morbidity and mortality in end-stage kidney disease (ESKD) patients and kidney transplantation (KT) recipients. Depression incidence after KT is unclear. We compared depression incidence among KT recipients, ESKD patients, and healthy controls (HCs). We analyzed a nationwide health insurance database in South Korea and identified patients who underwent KT during 2007–2015. Participants were matched for age, sex, and inclusion year. KT and ESKD patients were further matched for hypertension and diabetes mellitus history. The incidence rate (IR, per 1000 patients-years) of depression was compared among KT, ESKD, and HC groups. We analyzed 5,234 patients per group. Depression incidence was markedly lower in KT than ESKD patients (IR, 18.87 vs. 58.03; hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.30–0.36), but only slightly higher in KT recipients than in HCs (IR, 18.87 vs. 17.49; HR, 1.08; 95% CI, 0.96–1.22). After adjusting for comorbidities, the depression risk was lower in KT recipients than in HCs (adjusted HR, 0.52; 95% CI, 0.44–0.62; p < 0.001), whereas it remained higher in ESKD patients than in HCs (adjusted HR, 1.60; 95% CI, 1.36–1.87; p < 0.001). Among KT recipients, older age, female sex, lower economic status, and more comorbidities were associated with increased depression risk. Incident depression after KT increased mortality, graft failure, and death-censored graft failure risks in KT recipients. Our data suggest a broader role of KT than previously appreciated in terms of improving quality of life by reducing depression risk.

Abbreviations
CCI  Charlson comorbidity index
CI  confidence interval
CKD  chronic kidney disease
ESKD  end-stage kidney disease
HC  healthy controls
HR  hazard ratio
ICD-10  International Classification of Disease, 10th revision
IR  incidence rate
KT  kidney transplantation

Globally, depression is a common mental disorder, and is characterized by persistent sadness and loss of interest in activities. One of the contributor to the non-fatal burden of disease globally, depression is associated with substantial impairments in fulfilment of productive and social roles.
Depression is more common in patients with chronic kidney disease (CKD) than in those without CKD. Previous studies reported a prevalence of depression in CKD patients of about 21–38% [1-6]. Depression is associated with an increased risk of morbidity, mortality, and even progression to dialysis-dependent end-stage kidney disease (ESKD) [7-9]. As with other risk factors, it is necessary to explain how depression itself affects hard outcomes in ESKD patients. Possible mechanisms were suggested in several studies. Depression can induce non-adherence to proper diets, drugs, and medical service which can lead to malnutrition and decreased health status [9-11]. Also, in terms of cardiovascular diseases, there are reports that depression could affect biologic activities such as heart rate variability, inflammatory biomarker, and platelet function [12-14].

Kidney transplantation (KT) is the only therapeutic option for patients with ESKD. In addition to the recovery of kidney function, KT facilitates improvement in emotional and psychological states and ultimately offers a significant advantage in survival [14]. One meta-analysis showed that depression increases risk mortality in organ transplantation including KT [15]. Some studies identified no significant differences in depressive symptoms between KT recipients and CKD patients [16,19], but other studies have shown that transplantation could provide psychological improvements in KT recipients [20,21]. Despite several studies of mood disorder in KT and ESKD groups, it was difficult to find studies that accurately calculated and compared incidence of depression in those groups.

In this study, we aimed to explore the incidence of depression in KT recipients as compared with that in ESKD patients and healthy controls (HCs), and to determine the impact of depression in KT recipients.

Materials and methods

Ethical considerations. This study complied with the principles of the Declaration of Helsinki. The institutional review board of the Seoul National University Hospital (Institutional Review Board No. E-1904–111-1028) approved this study. The Ministry of Health and Welfare of South Korea approved to use the National Health Insurance Database (NHID). The need to obtain informed consent was waived because we used the data about study participants which were anonymized and de-identified.

Data source. We reviewed nationwide population-based data from NHID of South Korea, from January 2007 to December 2015. In South Korea, the National Health Insurance developed a registration system based on the specific code for each rare or incurable disease to provide benefits for medical costs. KT and ESKD are included in this rare, incurable disease category. The subjects of this study were selected based on the Interna-
tional Classification of Disease, 10th revision (ICD-10) code, rare or incurable disease code, prescription code, and procedure code. KT recipients who had received a KT from a living or deceased donor during the study period were selected based on the presence of a newly registered code for KT (V005) during the study period. The time of discharge was defined as the initiation of follow-up. ESKD patients were identified by the code for hemodialysis or peritoneal dialysis (Z49, Z99.2, V001, V003, O7011-7020, O7071-7075) for more than 3 months and who had never been registered with the code for KT (V005). Those who had not undergone either renal replacement therapy (RRT) or KT were classified by HCs. KT recipients were 1:1 matched with ESKD patients after adjustment for age, sex, inclusion year, the presence of hypertension and diabetes mellitus. Also, KT recipients were 1:1 matched with HCs after adjustment for age, sex, and inclusion year. Subjects were excluded based on the following criteria: (1) age less than 20 years, (2) previous diagnosis with depression before the start of this study, and (3) having received two or more organ transplantsations.

Data collection. Demographic characteristics, including age, sex, income level, and the type and duration of renal replacement therapy were collected from the baseline data in the NHID. Comorbidities, including hypertension, diabetes mellitus, dyslipidemia, were identified by the presence of ICD-10 codes or by two or more prescriptions of medications for hypertension, diabetes mellitus, and dyslipidemia within 1 year prior to the inclusion year. Charlson Comorbidity Index (CCI) score was calculated to assess the severity of the medical condition of the study subjects [22]. The history of immunosuppressants including desensitization, induction therapy, and maintenance were collected in KT recipients.

Study outcomes. We compared the incidence of depression in the three groups. Depression was identified by the ICD-10 code (F32, F33) which was newly registered in the study period. Since the follow-up of incident depression was performed until December 2017, all subjects had a follow-up period of at least 1 year.

The secondary outcome was the long-term effect of incident depression in KT recipients in terms of all-cause mortality, graft failure, and death-censored graft failure. All-cause mortality was defined as death for any reason after KT. Graft failure included death for any reason after KT or dialysis-related code issued 1 month after KT. Among these, all other events, except death, were separately defined as death-censored graft failure.

Statistical analysis. Continuous variables are presented as mean ± standard deviation, and categorical variables are expressed as percentages. We used the Kruskal–Wallis test for analysis of continuous variables. Chi-square test was used for analysis of categorical variables. The incidence rate (IR) of depression in the three groups was expressed by the number of events per 1000 person-years. Cox proportional hazard regression models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the risk of incident depression in KT recipients. The cumulative incidences of depression were compared among the three groups using the long-rank test. Time-dependent Cox regression analysis was used to evaluate the incidence of secondary outcomes, including all-cause mortality, graft failure, and death-censored graft failure. SAS 9.4 software (SAS Institute, Cary, NC, USA) was used to perform statistical analyses. Statistical significance was set at p < 0.05.
Results

Baseline characteristics. From 2007 to 2015, we found that total 13,179 patients underwent KT in South Korea. After 1:1 matching, KT, ESKD and HC groups included 5234 matched subjects, respectively (Fig. 1). Table 1 shows the baseline characteristics of the study participants. The mean age was 43.68 ± 10.4, and 65.44% of the patients were male in all groups. The ESKD and KT groups had lower economic status than the HC group, and the ESKD group had a lower economic status than the KT group. The prevalence of hypertension, diabetes mellitus, and dyslipidemia in the ESKD and KT groups was 91%, 31%, and 39%, respectively. In HC group, 13.39%, 5.04%, and 9.30% of participants had hypertension, diabetes mellitus, and dyslipidemia, respectively, which were all lower than those in ESKD and KT groups.

In the ESKD group, 73.67% received hemodialysis, 21.99% received peritoneal dialysis, and 4.34% were reported that both hemodialysis and peritoneal dialysis were performed. Among KT recipients, 41.88% underwent hemodialysis, 17.04% underwent peritoneal dialysis, and 35.88% had been never treated with any dialysis treatment. More than half of the ESKD and KT groups received dialysis treatment for more than a year. In the KT groups, desensitization treatment was performed in 13.99% before transplantation. Additionally, 93.58% of KT recipients received induction immunosuppressive therapy with antithymocyte globulin or basiliximab. Maintenance immunosuppressive therapy was administered to almost all KT recipients.

Incidence of depression. As shown in Tables 2 and 3, we analyzed the IR per 1000 person-years of incident depression in the three groups. KT recipients had a markedly lower incidence of depression during follow-up period than ESKD patients (IR, 18.87 vs. 58.03 per 1000 person-years; HR, 0.33; 95% CI, 0.30–0.37; p < 0.001) after adjusting for age, sex, income level, presence of hypertension, diabetes mellitus, and dyslipidemia, CCI score, and RRT duration.

Interestingly, after adjusting for comorbidity status, including hypertension, diabetes mellitus, and CCI score, KT recipients showed a lower risk of incident depression than HCs (adjusted HR, 0.52; 95% CI, 0.44–0.62; p < 0.001). On the other hand, risk of incident depression in ESKD patients remained at a higher risk compared with HCs (adjusted HR, 1.60; 95% CI, 1.36–1.87, p < 0.001). The cumulative risk for incident depression in the KT, ESKD, and HC groups are shown in Figs. 2 and 3.

Clinical characteristics of incident depression after KT. The differences in clinical characteristics according to the incidence of depression in KT recipients are shown in Table 4. In the KT group, KT recipients with depression showed a higher proportion of women, lower economic status, and higher prevalence of diabetes mellitus than those without depression. There was no statistically significant difference between the two groups according to the type and duration of RRT and immunosuppressant therapy.

In Table 5, we found that age > 60 years, female sex, lower economic status, and higher CCI score were risk factors for incident depression after KT. The type and duration of RRT before transplantation, desensitization, and type of immunosuppressant use were not statistically significant risk factors for the occurrence of depression.

Long-term effect of incident depression after KT. Table 6 and Fig. 4 show the long-term effects of incident depression as death, graft failure, and death-censored graft failure in KT recipients. Incident depression after KT was found to increase the risk of death (HR, 4.46; 95% CI, 3.24–6.13, p < 0.001), graft failure (HR, 2.57; 95% CI, 1.99–3.31, p < 0.001), and death-censored graft failure (HR, 2.10; 95% CI, 1.48–2.99, p < 0.001).
Table 1. Baseline characteristics of study population. Data are presented as the mean ± standard deviation, or n (%).

| Inclusion year | ESKD (N = 5234) | KT (N = 5234) | HC (N = 5234) | p-value |
|----------------|-----------------|--------------|--------------|---------|
| 2007           | 452 (8.64)      | 452 (8.64)   | 452 (8.64)   | 1       |
| 2008           | 551 (10.53)     | 551 (10.53)  | 551 (10.53)  |         |
| 2009           | 550 (10.51)     | 550 (10.51)  | 550 (10.51)  |         |
| 2010           | 529 (10.11)     | 529 (10.11)  | 529 (10.11)  |         |
| 2011           | 649 (12.40)     | 649 (12.40)  | 649 (12.40)  |         |
| 2012           | 670 (12.80)     | 670 (12.80)  | 670 (12.80)  |         |
| 2013           | 613 (11.71)     | 613 (11.71)  | 613 (11.71)  |         |
| 2014           | 639 (12.21)     | 639 (12.21)  | 639 (12.21)  |         |
| 2015           | 581 (11.10)     | 581 (11.10)  | 581 (11.10)  |         |
| Age            | 43.68 ± 10.4    | 43.68 ± 10.4 | 43.68 ± 10.4 | 1       |
| 20–29          | 528 (10.09)     | 528 (10.09)  | 528 (10.09)  |         |
| 30–39          | 1319 (25.20)    | 1319 (25.20) | 1319 (25.20) |         |
| 40–49          | 1746 (33.36)    | 1746 (33.36) | 1746 (33.36) |         |
| 50–59          | 1319 (25.20)    | 1319 (25.20) | 1319 (25.20) |         |
| 60–69          | 311 (5.94)      | 311 (5.94)   | 311 (5.94)   |         |
| ≥70            | 11 (0.21)       | 11 (0.21)    | 11 (0.21)    |         |
| Male           | 3425 (65.44)    | 3425 (65.44) | 3425 (65.44) | 1       |
| Income         | < 0.001         |              |              |         |
| Aid            | 1109 (21.19)    | 731 (13.97)  | 99 (1.89)    |         |
| Q1             | 1496 (28.58)    | 1031 (19.70) | 1382 (26.40) |         |
| Q2             | 1125 (21.49)    | 1057 (20.19) | 1302 (24.88) |         |
| Q3             | 866 (16.55)     | 1094 (20.90) | 1238 (23.65) |         |
| Q4             | 638 (12.19)     | 1321 (25.24) | 1213 (23.18) |         |
| Hypertension   | 4778 (91.29)    | 4778 (91.29) | 701 (13.39)  | < 0.001 |
| Diabetes mellitus | 1672 (31.94)  | 1672 (31.94) | 264 (5.04)   | < 0.001 |
| Dyslipidemia   | 2086 (39.85)    | 2813 (53.74) | 487 (9.30)   | < 0.001 |
| RRT type       | < 0.001         |              |              |         |
| None           | 0 (0)           | 1878 (35.88) | 5234 (100)   |         |
| HD             | 3856 (73.67)    | 2192 (41.88) | 0 (0)        |         |
| PD             | 1151 (21.99)    | 892 (17.04)  | 0 (0)        |         |
| Mixed          | 227 (4.34)      | 272 (5.20)   | 0 (0)        |         |
| RRT duration ≥ 1 year | 3091 (59.06) | 2640 (50.44) | 0 (0)       | < 0.001 |
| Desensitization | 0 (0)          | 732 (13.99)  | 0 (0)        | < 0.001 |
| Induction      | < 0.001         |              |              |         |
| No use         | 5234 (100)      | 336 (6.42)   | 5234 (100)   |         |
| ATG            | 0 (0)           | 353 (6.74)   | 0 (0)        |         |
| Basiliximab    | 0 (0)           | 4545 (86.84) | 0 (0)        |         |
| Maintenance    | < 0.001         |              |              |         |
| None           | 5234 (100)      | 143 (2.73)   | 5234 (100)   |         |
| Tacrolimus     | 0 (0)           | 4178 (79.82) | 0 (0)        |         |
| Cyclosporin    | 0 (0)           | 913 (17.44)  | 0 (0)        |         |

Table 2. Incidence rate and risk of depression in ESKD and KT groups. *IR: incidence rate per 1000 person-years. **Model 1 was adjusted for age and sex. ***Model 2 was adjusted for age, sex, income level, presence of hypertension, diabetes mellitus and dyslipidemia, CCI score, and RRT duration. ESKD end-stage kidney disease, KT kidney transplantation.
This nationwide population-based study aimed to evaluate the incidence of newly diagnosed depression in KT recipients compared with ESKD and HC groups. We found that the incidence of depression in the KT group was lower than that in the ESKD group, and unexpectedly, it was lower than that in the HC group after adjustment for comorbidities. Furthermore, we confirmed that incident depression adversely affected mortality and graft outcomes in KT recipients.

Depression is one of the most important public health issues. Persons with a personal or family history of psychiatric disorders, disability, and overall medical burden, particularly that of chronic diseases, are at higher risk of depression.

**Table 3.** Incidence rate and risk of depression in ESKD, KT and HC groups. *IR: incidence rate per 1000 person-years. **Model 1 was adjusted for age and sex. ***Model 2 was adjusted for age, sex, presence of hypertension, diabetes mellitus and dyslipidemia, and CCI score. ESKD end-stage kidney disease, KT kidney transplantation, HC healthy control.

|        | Total N | Incident depression | IR* | Model 1** | Model 2*** |
|--------|---------|---------------------|-----|-----------|------------|
|        |         |                     | HR (95% CI) | p-value | HR (95% CI) | p-value |
| ESKD   | 5234    | 1373                | 58.03 | 3.34 (3.02, 3.69) | < 0.001   | 1.60 (1.36, 1.87) | < 0.001 |
| KT     | 5234    | 568                 | 18.87 | 1.08 (0.96, 1.22) | 0.198     | 0.52 (0.44, 0.62) | < 0.001 |
| HC     | 5234    | 541                 | 17.49 | 1 (reference)   | 1 (reference) |         |

**Figure 2.** Cumulative risk for incident depression in KT and ESKD group. Abbreviation: ESKD, end-stage kidney disease; KT, kidney transplant.

**Discussion**
This nationwide population-based study aimed to evaluate the incidence of newly diagnosed depression in KT recipients compared with ESKD and HC groups. We found that the incidence of depression in the KT group was lower than that in the ESKD group, and unexpectedly, it was lower than that in the HC group after adjustment for comorbidities. Furthermore, we confirmed that incident depression adversely affected mortality and graft outcomes in KT recipients.

Depression is one of the most important public health issues. Persons with a personal or family history of psychiatric disorders, disability, and overall medical burden, particularly that of chronic diseases, are at higher risk of depression.
more susceptible to depression25,26. Depression is more common in patients with CKD than in the general population3,27. Depression is a common comorbidity in CKD patients, and it is associated with an increased risk of malnutrition, hospital admission and even early initiation of RRT3,9,10. In our study, ESKD patients showed a higher incidence of depression than HCs, even after adjustment for age, sex and comorbidities.

KT improves not only overall survival, but also quality of life in patients with ESKD16. Despite such advantages, KT recipients are challenged with rapid physical, psychological, and social changes5,28–30. Several studies have investigated the effect of KT on psychological aspects, and have found controversial results. Some studies showed that psychological distress of KT recipients did not seem to improve after KT, as compared with ESKD patients18,19,31. Other studies reported that KT was superior in relieving emotional distress and improving psychological well-being over hemodialysis or peritoneal dialysis in ESKD patients32–36. In a meta-analysis, the prevalence of depression, according to self-report or clinician-rated tools, was 26.6% in KT recipients and 39.3% in ESKD patients27. Old age37–41, female sex37,39–41, white race37, unemployment status and a poor financial situation16,38,39,42, and a low level of education39,40 are reported to increase the risk of depression in KT recipients. In terms of kidney function, KT recipients with a longer functional graft showed lower stages of depression33.

During our study period, among 5234 KT recipients, 568 subjects experienced incident depression after KT. The incidence was significantly lower than that in patients with ESKD, and was even lower than that in HC group after considering age, sex, and comorbidities. Based on this result, KT has psychological benefits beyond the recovery of kidney function. As with the results of many precious studies, several factors were associated with the risk of incident depression in KT recipients. Age > 60 years, female sex, poorer economic status, and higher CCI score could be predictive risk factors for depression in KT recipients. However, the type and duration of RRT and type of immunosuppressant were not related to an increased risk of depression.

We analyzed the long-term effect of incident depression after KT on all-cause mortality, graft failure, and death-censored graft failure. A prospective cohort study showed that depressive symptoms were not significantly associated with medical outcomes53. In contrast, many studies including meta-analysis found that depression may affect the disease process and graft survival17,30,44. Our results also showed a higher incidence of all-cause mortality, graft failure, and death-censored graft failure in group with depression than in the group without

Figure 3. Cumulative risk for incident depression in KT, ESKD and HC group. Abbreviation: ESKD, end-stage kidney disease; KT, kidney transplant; HC, healthy control.
depression in KT recipients through time-dependent Cox analysis. For KT recipients, it is very important to take immunosuppressive medication regularly and undergo regular examinations, including blood and urine tests and imaging. Depressive mood can reduce the patient’s adherence to medication and hospital visits and can discourage patients from modifying their lifestyle. Furthermore, the lack of social support due to the disconnection of relationships should also be considered.

There were several limitations to this study. Although this study used national health insurance data with a larger number of subjects than previous studies, this was a retrospective cohort study based on diagnosis and prescription history. Second, the assessment of depression was determined only by the ICD-10 code, and other methods, such as questionnaires and psychological evaluations, were not considered. Unfortunately, it was difficult to apply such a method to studies using national health insurance data. Third, due to the limited method for detecting the incident depression, the degree of depression was not considered in this study. If the degree of depression was discriminative, it would have been possible to compare the degree of depression for each group. Fourth, only depression was analyzed among several mental problems that could occur after KT. In future research, we will investigate the incidence of sleep disorders, eating disorders, anxiety, and neurological disorders, such as dementia, and their relationship with prognosis. Fifth, we could not review systemic corticosteroid therapy in all groups in this study. Corticosteroid is well-known drugs that have various side effects including psychiatric effect. We hope that further study must consider the corticosteroid as a variable in the evaluation of the incident depression. Sixth, we defined HCs as the absence of renal replacement therapy (RRT) or kidney transplantation (KT). HCs may include CKD patients as well as hypertension and diabetes, which may be a bias that affected the incidence of depression.

| Table 4. Clinical characteristics according to the presence of incident depression in KT group. Data are presented as the mean ± standard deviation, or n (%). KT kidney transplant, CCI Charlson Comorbidity Index, RRT renal replacement therapy, HD hemodialysis, PD peritoneal dialysis, ATG antithymocyte globulin. |
|-----------------|-----------------|-----------------|-----------------|
| Depression      | No (N = 4666)   | Yes (N = 568)   | p-value         |
| Age             |                 |                 |                 |
| 20–29           | 482 (10.33)     | 46 (8.10)       | 0.007           |
| 30–39           | 1204 (25.80)    | 115 (20.25)     |                 |
| 40–49           | 1550 (33.22)    | 196 (34.51)     |                 |
| 50–59           | 1151 (24.67)    | 168 (29.58)     |                 |
| 60–69           | 269 (5.77)      | 42 (7.39)       |                 |
| ≥70             | 10 (0.21)       | 1 (0.18)        |                 |
| Male            | 3088 (66.18)    | 337 (59.33)     | 0.001           |
| Income          |                 |                 | < 0.001         |
| Aid             | 594 (12.73)     | 137 (24.12)     |                 |
| Q1              | 925 (19.82)     | 106 (18.66)     |                 |
| Q2              | 962 (20.62)     | 95 (16.73)      |                 |
| Q3              | 986 (21.13)     | 108 (19.01)     |                 |
| Q4              | 1199 (25.70)    | 122 (21.48)     |                 |
| Hypertension    | 4265 (91.41)    | 513 (90.32)     | 0.385           |
| Diabetes mellitus| 1458 (31.25)   | 214 (37.68)     | 0.002           |
| Dyslipidemia    | 2498 (53.54)    | 315 (55.46)     | 0.386           |
| RRT type        |                 |                 | 0.079           |
| None            | 1686 (36.13)    | 192 (33.80)     |                 |
| HD              | 1947 (41.73)    | 245 (43.13)     |                 |
| PD              | 781 (16.74)     | 111 (19.54)     |                 |
| Mixed           | 252 (5.40)      | 20 (3.52)       |                 |
| RRT duration ≥ 1 year | 2345 (50.26) | 295 (51.94) | 0.450 |
| Desensitization| 662 (14.19)     | 70 (12.32)      | 0.227           |
| Induction       |                 |                 | 0.112           |
| No use          | 290 (6.22)      | 46 (8.10)       |                 |
| ATG             | 322 (6.90)      | 31 (5.46)       |                 |
| Basiliximab     | 4054 (86.88)    | 491 (86.44)     |                 |
| Maintenance     |                 |                 | 0.348           |
| None            | 131 (2.81)      | 12 (2.11)       |                 |
| Tacrolimus      | 3731 (79.96)    | 447 (78.70)     |                 |
| Cyclosporin     | 804 (17.23)     | 109 (19.19)     |                 |
Table 5. Predictive risk factors for incident depression in KT group. KT kidney transplantation, CCI Charlson Comorbidity Index, RRT renal replacement therapy, HD hemodialysis, PD peritoneal dialysis, ATG antithymocyte globulin.

|                | Univariate |                | Multivariate |                |
|----------------|------------|----------------|--------------|----------------|
|                | HR (95% CI)| p-value        | HR (95% CI)  | p-value        |
| Age            |            |                |              |                |
| 20–29          | 0.56 (0.41, 0.78) | <0.001         | 0.60 (0.43, 0.84) | <0.001         |
| 30–39          | 0.59 (0.47, 0.75) | 0.58 (0.45, 0.74) | 0.60 (0.43, 0.84) | <0.001         |
| 40–49          | 0.80 (0.65, 0.98) | 0.76 (0.62, 0.94) | 0.60 (0.43, 0.84) | <0.001         |
| 50–59          | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| 60–69          | 1.15 (0.82, 1.61) | 1.21 (0.86, 1.70) | 1.15 (0.82, 1.61) | 0.009          |
| ≥70            | 1.01 (0.14, 7.21) | 1.25 (0.17, 8.93) | 1.01 (0.14, 7.21) | 0.009          |
| Sex            |            |                |              |                |
| Male           | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| Female         | 1.25 (1.06, 1.48) | 1.32 (1.11, 1.56) | 1.25 (1.06, 1.48) | 0.009          |
| Income         |            |                |              |                |
| Aid            | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| Q1             | 0.56 (0.44, 0.73) | 0.54 (0.41, 0.70) | 0.56 (0.44, 0.73) | 0.001          |
| Q2             | 0.48 (0.37, 0.63) | 0.45 (0.35, 0.59) | 0.48 (0.37, 0.63) | 0.001          |
| Q3             | 0.53 (0.41, 0.69) | 0.50 (0.39, 0.65) | 0.53 (0.41, 0.69) | 0.001          |
| Q4             | 0.50 (0.39, 0.64) | 0.43 (0.33, 0.56) | 0.50 (0.39, 0.64) | 0.001          |
| CCI score      |            |                |              |                |
| 1–2            | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| 3–4            | 1.21 (0.90, 1.63) | 1.17 (0.87, 1.58) | 1.21 (0.90, 1.63) | 0.001          |
| ≥5             | 1.73 (1.30, 2.30) | 1.56 (1.16, 2.10) | 1.73 (1.30, 2.30) | 0.001          |
| Hypertension   | 0.90 (0.69, 1.19) | 0.477            | 0.90 (0.69, 1.19) | 0.927          |
| Diabetes mellitus | 1.35 (1.14, 1.60) | 1.08 (0.90, 1.31) | 1.35 (1.14, 1.60) | 0.927          |
| Dyslipidemia   | 1.12 (0.95, 1.32) | 1.11 (0.93, 1.31) | 1.12 (0.95, 1.32) | 0.251          |
| RRT type       |            |                |              |                |
| None           | 0.87 (0.72, 1.05) | 0.87 (0.67, 1.14) | 0.87 (0.72, 1.05) | 0.254          |
| HD             | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| PD             | 1.09 (0.87, 1.37) | 1.10 (0.87, 1.38) | 1.09 (0.87, 1.37) | 0.254          |
| Mixed          | 0.70 (0.45, 1.11) | 0.74 (0.47, 1.17) | 0.70 (0.45, 1.11) | 0.254          |
| RRT duration ≥1 year | 1.12 (0.95, 1.32) | 0.92 (0.72, 1.19) | 1.12 (0.95, 1.32) | 0.527          |
| Desensitization | 1.05 (0.82, 1.35) | 1.05 (0.81, 1.36) | 1.05 (0.82, 1.35) | 0.696          |
| Induction      |            |                |              |                |
| No use         | 0.99 (0.63, 1.57) | 1.10 (0.68, 1.78) | 0.99 (0.63, 1.57) | 0.772          |
| ATG            | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| Basiliximab    | 1.02 (0.71, 1.46) | 0.98 (0.68, 1.41) | 1.02 (0.71, 1.46) | 0.619          |
| Maintenance    |            |                |              |                |
| None           | 0.83 (0.47, 1.47) | 0.88 (0.49, 1.59) | 0.83 (0.47, 1.47) | 0.619          |
| Tacrolimus     | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference)  |
| Cyclosporin    | 0.91 (0.74, 1.12) | 0.90 (0.72, 1.12) | 0.91 (0.74, 1.12) | 0.619          |

Table 6. Risk of death, graft failure and death-censored graft failure according to the presence of depression in KT group. KT kidney transplantation, DCGF death-censored graft failure.

| Depression | N  | Event | HR (95% CI) | p-value |
|------------|----|-------|-------------|---------|
| Death      |    |       |             |         |
| No         | 5234 | 195   | 1 (reference) | <0.001  |
| Yes        | 568  | 49    | 4.46 (3.24, 6.13) | <0.001  |
| Graft failure |    |       |             |         |
| No         | 5234 | 489   | 1 (reference) | <0.001  |
| Yes        | 515  | 69    | 2.57 (1.99, 3.31) | <0.001  |
| DCGF       |    |       |             |         |
| No         | 5234 | 312   | 1 (reference) | <0.001  |
| Yes        | 515  | 35    | 2.10 (1.48, 2.99) | <0.001  |
In conclusion, KT recipients showed a markedly lower risk of incident depression than ESKD patients and even matched HCs after adjustment for comorbidities. There was a negative association incident depression on mortality and graft outcomes. If further research shows that the treatment of depression in KT recipients can improve long-term renal outcome, the implications of this study will be further strengthened. Attention to the psychological aspects of KT recipients is important when managing patients undergoing KT. KT has a broader role than originally conceived. Moreover, the management of depression in patients with ESKD and KT recipients may have a significant impact on the patient’s prognosis.

Data availability

The datasets generated and/or analyzed in the current study are available from the corresponding author on reasonable request.

Received: 8 April 2022; Accepted: 19 September 2022
Published online: 20 October 2022

References

1. Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9 (2020).

2. Patel, V. et al. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities. Washington (DC): The International Bank for Reconstruction and Development. 3rd edn Vol. 2 (2016).

3. Hedayati, S. S., Minhajuddin, A. T., Toto, R. D., Morris, D. W. & Rush, A. J. Prevalence of major depressive episode in CKD. J. Nephrol. 79, 228–232. https://doi.org/10.1016/j.jnephrol.2015.01.009 (2015).

4. Balogun, R. A. et al. Association of depression and antidepressant use with mortality in a large cohort of patients with nondialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 7, 1793–1800. https://doi.org/10.2215/CJN.02650312 (2012).

5. Chilcott, J., Spencer, B. W., Maple, H. & Mamode, N. Depression and kidney transplantation. Transplantation 97, 717–721. https://doi.org/10.1097/TP.0000438212.72960.ae (2014).

6. Andrade, C. P. et al. Evaluation of depressive symptoms in patients with chronic renal failure. J. Nephrol. 23, 168–174 (2010).

7. Chiang, H. H. et al. Increased risk of progression to dialysis or death in CKD patients with depressive symptoms: A prospective 3-year follow-up cohort study. J. Psychosom. Res. 79, 228–232. https://doi.org/10.1016/j.jpsychores.2015.01.009 (2015).

8. Kimmel, P. L., Wechs, K. & Peterson, R. A. Survival in hemodialysis patients: the role of depression. J. Am. Soc. Nephrol. 4, 12–27. https://doi.org/10.1681/ASN.V4112 (1993).

9. Hedayati, S. S. et al. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA 303, 1946–1953. https://doi.org/10.1001/jama.2010.619 (2010).

10. Koo, J. R. et al. Association of depression with malnutrition in chronic hemodialysis patients. Am. J. Kidney Dis. 41, 1037–1042. https://doi.org/10.1016/s0272-6386(03)00201-4 (2003).

11. Ziegelstein, R. C. et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch. Intern. Med. 160, 1818–1823. https://doi.org/10.1001/archinte.160.12.1818 (2000).

12. Empiana, J. P. et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the prospective epidemiological study of myocardial infarction (PRIME). Circulation 111, 2299–2305. https://doi.org/10.1161/01.CIR.0000164203.54111.AE (2005).

13. Otte, C. et al. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: The heart and soul study. Biol. Psychiatry 56, 241–247. https://doi.org/10.1016/j.biopsych.2004.06.003 (2004).

14. Carney, R. M. et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 104, 2024–2028. https://doi.org/10.1161/hc4201.097834 (2001).

15. Serebruany, V. L. et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108, 939–944. https://doi.org/10.1161/01.CIR.0000085163.21752.0A (2003).

16. Zelle, D. M. et al. Impact of depression on long-term outcome after renal transplantation: a prospective cohort study. Transplantation 94, 1033–1040. https://doi.org/10.1097/TP0b013e31826bc3c8 (2012).

17. Dew, M. A. et al. Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: A systematic review and meta-analysis. Transplantation 100, 988–1003. https://doi.org/10.1097/TP0000000000009901 (2015).

Figure 4. Cumulative risk for death, graft failure, and death censored graft failure according to presence of incident depression in KT group ((A): death, (B): graft failure, (C): death censored graft failure).

(A) Death

(B) Graft failure

(C) Death censored graft failure
Author contributions
Participated in research design: S.C., J.E.K., M.Y., S.H.B., H.L., Y.C.K. Participated in the collection of the data: S.C., K.H., H.L., Y.C.K. Participated in the data analysis: S.C., K.H., H.L., Y.C.K. Participated in the writing of the paper: S.C., Y.C.K. Participated in editing and revising the manuscript: S.C., S.P., J.E.K., M.Y., S.H.B., H.L., D.K.K., K.W., J.E.K., Y.C.K.

Funding
This study was supported by a grant from the Ministry of Health and Welfare, Republic of Korea (Grant Number: H118C1604). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.C.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
